TY - JOUR
T1 - Multisite Assessment of Optical Genome Mapping for Analysis of Structural Variants in Constitutional Postnatal Cases
AU - Iqbal, M. Anwar
AU - Broeckel, Ulrich
AU - Levy, Brynn
AU - Skinner, Steven
AU - Sahajpal, Nikhil S.
AU - Rodriguez, Vanessa
AU - Stence, Aaron
AU - Awayda, Kamel
AU - Scharer, Gunter
AU - Skinner, Cindy
AU - Stevenson, Roger
AU - Bossler, Aaron
AU - Nagy, Peter L.
AU - Kolhe, Ravindra
N1 - Funding Information:
Disclosures: R.K. has received honoraria, and/or travel funding, and/or research support from Illumina, Asuragen, Qiagen, Perkin Elmer Inc., Bionano Genomics, Agena, Agendia, PGDx, Thermo Fisher Scientific, Cepheid, and BMS. N.S.S. owns a limited number of personal stocks of Bionano Genomics. P.L.N. owns a limited number of personal stocks in Bionano. All other authors declare no conflicts of interest.
Funding Information:
Supported by Bionano Genomics, including coverage of chips and reagents as well as project management, bioinformatics, and analyst efforts; the Childrens Research Institute; Childrens Wisconsin; and the Department of Pathology and Laboratory Medicine, University of Rochester Medical Center (Rochester, NY). Disclosures: R.K. has received honoraria, and/or travel funding, and/or research support from Illumina, Asuragen, Qiagen, Perkin Elmer Inc., Bionano Genomics, Agena, Agendia, PGDx, Thermo Fisher Scientific, Cepheid, and BMS. N.S.S. owns a limited number of personal stocks of Bionano Genomics. P.L.N. owns a limited number of personal stocks in Bionano. All other authors declare no conflicts of interest.
Funding Information:
Supported by Bionano Genomics , including coverage of chips and reagents as well as project management, bioinformatics, and analyst efforts; the Childrens Research Institute ; Childrens Wisconsin ; and the Department of Pathology and Laboratory Medicine , University of Rochester Medical Center (Rochester, NY).
Publisher Copyright:
© 2023 Association for Molecular Pathology and American Society for Investigative Pathology
PY - 2023/3
Y1 - 2023/3
N2 - This study compares optical genome mapping (OGM) performed at multiple sites with current standard-of-care (SOC) methods used in clinical cytogenetics. This study included 50 negative controls and 359 samples from individuals (patients) with suspected genetic conditions referred for cytogenetic testing. OGM was performed using the Saphyr system and Bionano Access software version 1.7. Structural variants, including copy number variants, aneuploidy, and regions of homozygosity, were detected and classified according to American College of Medical Genetics and Genomics guidelines. Repeated expansions in FMR1 and contractions in facioscapulohumeral dystrophy 1 were also analyzed. OGM results were compared with SOC for technical concordance, clinical classification concordance, intrasite and intersite reproducibility, and ability to provide additional, clinically relevant information. Across five testing sites, 98.8% (404/409) of samples yielded successful OGM data for analysis and interpretation. Overall, technical concordance for OGM to detect previously reported SOC results was 99.5% (399/401). The blinded analysis and variant classification agreement between SOC and OGM was 97.6% (364/373). Replicate analysis of 130 structural variations was 100% concordant. On the basis of this demonstration of the analytic validity and clinical utility of OGM by this multisite assessment, the authors recommend this technology as an alternative to existing SOC tests for rapid detection and diagnosis in postnatal constitutional disorders.
AB - This study compares optical genome mapping (OGM) performed at multiple sites with current standard-of-care (SOC) methods used in clinical cytogenetics. This study included 50 negative controls and 359 samples from individuals (patients) with suspected genetic conditions referred for cytogenetic testing. OGM was performed using the Saphyr system and Bionano Access software version 1.7. Structural variants, including copy number variants, aneuploidy, and regions of homozygosity, were detected and classified according to American College of Medical Genetics and Genomics guidelines. Repeated expansions in FMR1 and contractions in facioscapulohumeral dystrophy 1 were also analyzed. OGM results were compared with SOC for technical concordance, clinical classification concordance, intrasite and intersite reproducibility, and ability to provide additional, clinically relevant information. Across five testing sites, 98.8% (404/409) of samples yielded successful OGM data for analysis and interpretation. Overall, technical concordance for OGM to detect previously reported SOC results was 99.5% (399/401). The blinded analysis and variant classification agreement between SOC and OGM was 97.6% (364/373). Replicate analysis of 130 structural variations was 100% concordant. On the basis of this demonstration of the analytic validity and clinical utility of OGM by this multisite assessment, the authors recommend this technology as an alternative to existing SOC tests for rapid detection and diagnosis in postnatal constitutional disorders.
UR - http://www.scopus.com/inward/record.url?scp=85148677476&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148677476&partnerID=8YFLogxK
U2 - 10.1016/j.jmoldx.2022.12.005
DO - 10.1016/j.jmoldx.2022.12.005
M3 - Article
C2 - 36828597
AN - SCOPUS:85148677476
SN - 1525-1578
VL - 25
SP - 175
EP - 188
JO - Journal of Molecular Diagnostics
JF - Journal of Molecular Diagnostics
IS - 3
ER -